Zymeworks Announces Participation In Upcoming Investor Conferences
Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
Zymeworks Announces Participation In Upcoming Investor Conferences
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Zymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI)
Today we announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. Zanidatamab in combination with chemotherapy was well tolerated with encouraging and durable antitumor activity for first-line treatment of advanced HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) in the ongoing Phase 2 clinical study. A poster with an updated data […]
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Zymeworks Presents Preclinical Data on TLR7 ISACs technology at the Society for Immunotherapy of Cancer (SITC) Conference
Today we presented preclinical data associated with our TLR7 ISACs technology. The poster presentation titled “Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)” shows the potential of using novel purine-based TLR7 agonists as payloads for ISACs. ISACs consist of antibodies conjugated to immune stimulants and are designed to induce antitumor immune […]
